ScholarLens Back to search
2012•International Journal of Immunopathology and PharmacologyOpen access

Switch to Icatibant in a Patient Affected by Hereditary Angioedema with High Disease Activity: A Case Report

Davide Firinu, Maria Pina Barca, Lorenzo Serusi, M. M. Lorrai, M. M. Peralta, Paolo Emilio Manconi, S.R. Del Giacco

Open full text 2 citations

Abstract

Icatibant, an antagonist of the bradykinin B2 receptor, was approved for the treatment of acute attacks of hereditary angioedema in the EU in 2008. This paper presents the case of a 65-year-old woman affected by frequent acute attacks of hereditary angioedema who benefitted from a change of therapy to icatibant, following years of treatment with C1-inhibitor.

Open-access reader

About this research paper

What this paper is about

Icatibant, an antagonist of the bradykinin B2 receptor, was approved for the treatment of acute attacks of hereditary angioedema in the EU in 2008. This paper presents the case of a 65-year-old woman affected by frequent acute attacks of hereditary angioedema who benefitted from a change of therapy to icatibant, following years of treatment with C1-inhibitor.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Icatibant, an antagonist of the bradykinin B2 receptor, was approved for the treatment of acute attacks of hereditary angioedema in the EU in 2008. This paper presents the case of a 65-year-old woman affected by frequent acute attacks of hereditary angioedema who benefitted from a change of therapy to icatibant, following years of treatment with C1-inhibitor.

Key concepts: Icatibant, Hereditary angioedema, Medicine, Bradykinin, C1-inhibitor, B2 receptor, Angioedema, Dermatology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Switch to Icatibant in a Patient Affected by Hereditary Angioedema with High Disease Activity: A Case Report — Research Paper | ScholarLens